Sign Out
Pregnancy: There are no or limited amount of data from the use of Remdesivir in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see Pharmacology: Preclinical Studies under Actions). Remdesivir should not be used during pregnancy unless the clinical condition of the women requires treatment with it.
Women of child-bearing potential have to use effective contraception during treatment.
Breast-feeding: It is unknown whether Remdesivir is excreted in human milk or the effects on the breast-fed infant, or the effects on milk production.
In animal studies, the nucleoside analog metabolite GS-441524 has been detected in the blood of nursing rat pups of mothers given Remdesivir. Therefore, excretion of Remdesivir and/or metabolites into the milk of lactating animals can be assumed.
Because of the potential for viral transmission to SARS-CoV-2-negative infants and adverse reactions from the drug in breast-feeding infants, a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Remdesivir therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: No human data on the effect of Remdesivir on fertility are available. In male rats, there was no effect on mating or fertility with Remdesivir treatment. In female rats, however, an impairment of fertility was observed. The relevance for humans is unknown.
